{"database": "press", "table": "releases", "rows": [["https://www.welch.senate.gov/welch-leads-colleagues-in-demanding-transparency-from-hhs-on-trumprx-new-pricing-deals-with-pfizer-and-astrazeneca/", "Welch Leads Colleagues in Demanding Transparency from HHS on \u201cTrumpRx,\u201d New Pricing Deals with Pfizer and AstraZeneca", "2025-11-07", "2025", "2025-11", "Democrat", "Senate", "VT", "Peter Welch", "W000800", "www.welch.senate.gov", "welch", "https://www.welch.senate.gov/category/press-release/page/", "scraper", "Senators request answers on structure of \u201cTrumpRx\u201d and how recent drug pricing agreements will impact Medicare and Medicaid benefits\n\nWASHINGTON, D.C. \u2013 U.S. Senator Peter Welch (D-Vt.), a member of the Senate Finance Committee, this week led six Senate Democrats in demanding transparency from the Department of Health and Human Services (HHS) on the scope, structure, and legal authority of the Trump Administration\u2019s newly unveiled \u201cTrumpRx\u201d platform. In their letter to Health Secretary Robert F. Kennedy, Jr., the Senators requested answers about how the Administration\u2019s recent drug pricing arrangements with pharmaceutical companies Pfizer and AstraZeneca will impact patients, and existing state and federal drug pricing programs.\n\nThe Senators highlighted that while the President\u2019s \u201cTrumpRx\u201d program promises \u201cdeep discounts\u201d on brand-name medications, the Administration has not provided any detailed information on the legality and implementation of the program: \u201cWhile the announcement of TrumpRx emphasized affordability and access, direct-to-patient sales programs help only a fraction of patients\u2014those who can afford to buy their drugs out of pocket. Additionally, these direct-to-consumer discount programs do nothing to address long-term costs.\u201d\n\n\u201cThe Administration\u2019s announcement of a new Most Favored Nation (MFN)-style deal with Pfizer and AstraZeneca included much fanfare but few details about how the program will be implemented. State Medicaid programs and safety net providers rely on the Medicaid Drug Rebate Program to ensure vulnerable patients get the lowest prices,\u201d the Senators continued. \u201cThe introduction of a new, preferential pricing arrangement with individual manufacturers, absent a statutory framework, threatens to undermine these longstanding programs.\u201d\n\nThe Senators also raised concerns about potential conflicts of interest between TrumpRx and the Trump family\u2019s business dealings: \u201cBlinkRx\u2014a direct-to-patient sales platform of which President Trump\u2019s son, Donald Trump Jr., is a board member\u2014will reportedly be facilitating the TrumpRx program. The Wall Street Journal recently reported President Trump\u2019s upcoming \u2018Future of Pharmaceuticals\u2019 summit will be co-hosted by BlinkRx and 1789 Capital, a venture capital firm in which Mr. Trump Jr. is a partner. The firm invested in BlinkRx less than a year ago. These connections raise questions about potential conflicts of interest between TrumpRx and the Trump family\u2019s business dealings.\u201d\n\n\u201cGiven the wide-reaching implications for Medicare and Medicaid beneficiaries, and the 340B safety-net covered entities, it is imperative that the Department provide Congress and the public with immediate transparency regarding the structure, impact, and legality of these initiatives,\u201d the Senators concluded.\n\nIn addition to Senator Welch, the letter is cosigned by Sens. Ben Ray Luj\u00e1n (D-N.M.), Elizabeth Warren (D-Mass.), Amy Klobuchar (D-Minn.), Jeff Merkley (D-Ore.), Bernie Sanders (I-Vt.), and Angela Alsobrooks (D-Md.).\n\nRead the full text of the Senators\u2019 letter to HHS Secretary Robert F. Kennedy, Jr.\n\n###", 1, "2026-03-30T01:40:41Z", "2026-04-06T19:52:45Z"]], "columns": ["url", "title", "date", "year", "month", "party", "chamber", "state", "member_name", "bioguide_id", "domain", "scraper", "source", "date_source", "text", "has_text", "collected_at", "updated_at"], "primary_keys": ["url"], "primary_key_values": ["https://www.welch.senate.gov/welch-leads-colleagues-in-demanding-transparency-from-hhs-on-trumprx-new-pricing-deals-with-pfizer-and-astrazeneca/"], "units": {}, "query_ms": 0.8529720362275839, "source": "dwillis/congress-press", "source_url": "https://github.com/dwillis/congress-press", "license": "MIT", "license_url": "https://github.com/dwillis/congress-press/blob/main/LICENSE"}